Skip to main content
Premium Trial:

Request an Annual Quote

Apton Biosystems Raises $24M in Series A Funding

NEW YORK – Apton Biosystems, a Pleasanton, California-based firm developing sequencing and protein detection technology, said on Wednesday that it has raised $24 million in Series A financing.

Kern Capital led the round, joined by Casdin Capital and Khosla Ventures. Jay Kern has joined Apton's board of directors.

The firm plans to use the funding to continue development of its Super-Res sequencing and single-molecule proteomics detection systems.

"Genomics and advanced proteomics are utilized in a minority of clinical applications today, but have the potential to unlock the answers to every facet of human biology," Apton CEO John Hanna said in a statement. "This funding allows us to continue building the team and technology to address the challenges in reaching the scale necessary for routine clinical use."

Founded in 2012, Apton has designed optical systems for sequencing and protein detection. It has also received funding from Samsung Catalyst Fund and Cowen Investments.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.